Tocilizumab discontinuation after remission achievement in patients with adult-onset Still's disease.
Hiroya TamaiYasushi KondoTsutomu TakeuchiYuko KanekoPublished in: Rheumatology (Oxford, England) (2024)
The recurrence rate after tocilizumab discontinuation was 50% in 1 year. Patients who remained in remission with a longer interval of tocilizumab administration and lower prednisolone dose were likely to succeed in the withdrawal of tocilizumab.